Navigation Links
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
Date:6/29/2010

clusive licensee of approximately 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development of drugs for metabolic diseases, including the development, activity, therapeutic potential and safety of ISIS 113715 and ISIS-GCGRRx in the treatment of type 2 diabetes.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

<
'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
2. Abbott 2009 Global Citizenship Report Highlights Companys Progress in Redefining Responsibility
3. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
4. LightLab Highlights OCT Market Leadership at the Society for Cardiovascular Angiography and Interventions
5. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
6. Bionovo Announces 2009 Highlights and Year-End Financial Results
7. Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010
8. New Publication Highlights 2-Year Durability and Effectiveness of Macroplastique(R)
9. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
10. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
11. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015   KaloBios Pharmaceuticals, Inc . (Nasdaq: ... developing innovative therapies to benefit patients with diseases of ... today that the U.S. Food and Drug Administration (FDA) ... for KB003, an anti-GM-CSF monoclonal antibody (mAb), in patients ... is now active. The acceptance of this ...
(Date:7/29/2015)... , July 27, 2015 Research ... addition of the "Global Neurostimulation Devices Market ... The analysts forecast the global neurostimulation devices market ... the period 2014-2019. The report, Global ... on an in-depth market analysis with inputs from ...
(Date:7/29/2015)... Inc., a privately-held regenerative medicine company with the first stem cell-derived ... today announced the opening of a second site in its Phase ... olerability, and E fficacy of VC-01™ Combination P roduct ... the first in Canada , will be at ... Alberta.  The lead Edmonton ...
Breaking Medicine Technology:KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5Global Neurostimulation Devices Market 2015-2019 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4
... SACRAMENTO, Calif., Dec. 13, 2011  The California Academy of ... with NeedyMeds, a national non-profit organization, to launch a ... the costs of their medications and other health care ... be used by all California families to save up ...
... The U.S. Food and Drug Administration today announced ... surgical centers and the marketing firm 1-800-GET-THIN LLC, ... device used for weight loss in obese adults. ... FDA issued Warning Letters to Bakersfield Surgery Institute ...
Cached Medicine Technology:California Academy of Physician Assistants Launches Prescription Drug Discount Card to Help California Families Stay Healthy, Manage Rising Costs of Health Care 2California Academy of Physician Assistants Launches Prescription Drug Discount Card to Help California Families Stay Healthy, Manage Rising Costs of Health Care 3FDA Issues Warning Letters for Misleading Advertising of Lap-Band 2FDA Issues Warning Letters for Misleading Advertising of Lap-Band 3
(Date:7/29/2015)... ... July 29, 2015 , ... Ticket Down is a reliable source of authentic ... USA . , The international soccer schedule of matches played on American soil ... September 8th, one of the world’s greatest teams, Brazil, will travel to North America ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to The ... a gene which is directly responsible for stimulating and perpetuating alcohol use disorders. Humans ... journal entitled Proceedings of the National academy of Sciences, and has given researchers inklings ...
(Date:7/29/2015)... ... 2015 , ... CrossFit 269, offering a nationally franchised cross-training ... & Conditioning. , The name change coincides with the release of its new ... over the past three years,” according to Jack Kelly, the center’s owner and ...
(Date:7/29/2015)... ... 29, 2015 , ... For the second year in a row, the management ... the 50 fastest growing companies in Jacksonville. This annual list is compiled by the ... a team of Vast Bridges staffers were on hand to receive the award naming ...
(Date:7/29/2015)... ... July 29, 2015 , ... CanAm Enterprises, LLC (“CanAm”) is ... the past month! I-829 approvals have been granted to investors in four different CanAm ... Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center project in ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3
... (August 1, 2009)Patients with second primary lung cancers (SPLC), ... (OPLC), are more likely to have localized disease at ... receive surgical treatment rather than radiation treatment. However, patients ... mortality, Fox Chase Cancer Center researchers reported today at ...
... NASHVILLE, Tenn., Aug. 1 HCA Healthcare announces the following Webcast: , , ... , When: August 6, 2009 @ ... http://www.videonewswire.com/event.asp?id=60459 , , How: ... the address above. , , Contact: ...
... ... its entry into the interventional radiology marketplace with the nationwide launch of its new ... ... entry into the interventional radiology marketplace with the nationwide launch of its new ...
... ... II in Webinar Series on "How Generation and Gender Impact Physician Engagement" , ... Charlotte, N.C. (Vocus) July 31, 2009 -- ... Differences in Physician Engagement." The free hour-long ,webinar will be broadcast on Wednesday, ...
... ... are reported to be refusing travellers with symptoms similar to flu to board planes, travel ... ... of all calls to AA Travel Insurance are now enquiries from travellers concerned about whether ...
... People travelling with no cover ... Cardiff ... widespread, the advice is clear for those travelling abroad: it is paramount adequate insurance is in ... continues to be a risk to the public. These policies will cover the traveller and holidays ...
Cached Medicine News:Health News:Fox Chase researchers identify differences in treatments and outcomes of patients with second primary lung cancers versus those with one primary lung cancer 2Health News:New DrainEx(TM) Catheter Simplifies Insertion and Replacement 2Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 2Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 3Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 2Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 3Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 4Health News:Swine Flu Advice from Confused.com 2Health News:Swine Flu Advice from Confused.com 3
... AlphaPette Pipettor is the #1 Pipettor ... accuracy, comfort, and reliability. Continuously adjustable. ... readout sub-micrometer. Easy interchangeable ejector buttons ... hands. Adjustable rapid pipet tip ejector ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
... Hamilton is precision, ergonomics, and value!, ... fatigue with soft non-slip, contoured handle ... smooth, light plunger spring action , ... sterilization without the need for recalibration ...
... Pipettor is the #1 Pipettor for ... comfort, and reliability. Continuously adjustable. Features ... sub-micrometer. Easy interchangeable ejector buttons to ... Adjustable rapid pipet tip ejector with ...
Medicine Products: